Lupin's Pune Biotech Facility Receives Four FDA Observations in Pre-Approval Inspection

Lupin Limited's Pune Biotech facility underwent a U.S. FDA Pre-Approval Inspection from September 8 to 19, resulting in four observations. The company plans to respond within the stipulated timeframe and reaffirms its commitment to CGMP quality standards. Separately, Lupin received FDA approval for generic Lenalidomide Capsules. The company's shares closed 0.51% lower at Rs 2,057.00 following the news.